This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of GERD on Daily Life (NIS) (Alegria)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 15, 2007
Last updated: January 25, 2012
Last verified: January 2012
The aim of this study is to gather epidemiological data in a population of GERD patients in primary care with a history of erosive esophagitis (less than or equal to 3 years).


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life of GERD in Patients With Erosive Gastroesophageal Reflux Disease.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To gather epidemiological data in a population of GERD patients [ Time Frame: After collection of all questionnaires ]

Secondary Outcome Measures:
  • To evaluate the added value of a new patient questionnaire (GERD Impact Scale) as a useful tool for the initial and long-term management of GERD patients: determination of the appropriate treatment and evaluation of the response to treatment. [ Time Frame: After collection of all questionnaires ]

Enrollment: 2001
Study Start Date: June 2006
Study Completion Date: March 2008

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary & Specialty care units

Inclusion Criteria:

  • Patients with erosive esophagitis (endoscopical findings according to the Los Angeles Classification; grade A-D) currently not treated with a proton pump inhibitor, for whom the general practitioner (GP) has decided to initiate or change the treatment for GERD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00545883

  Show 112 Study Locations
Sponsors and Collaborators
Principal Investigator: E. Louis, PR ULG
  More Information

Responsible Party: AstraZeneca Identifier: NCT00545883     History of Changes
Other Study ID Numbers: NIS-GBE-NEX-2006/1
Study First Received: October 15, 2007
Last Updated: January 25, 2012

Keywords provided by AstraZeneca:
PPI processed this record on September 21, 2017